Edition:
India

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

73.55EUR
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
€73.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,083,008
52-wk High
€92.97
52-wk Low
€72.63

Select another date:

Thu, Dec 14 2017

BRIEF-Mylan Announces U.S. Regulator's Review Proceedings On All Claims Against Sanofi's Lantus Patents

* MYLAN ANNOUNCES THE U.S. PATENT AND TRADEMARK APPEAL BOARD INSTITUTES INTER PARTES REVIEW PROCEEDINGS ON ALL CLAIMS AGAINST SANOFI'S LANTUS® PATENTS

France's Sanofi pins hopes on new drugs after setbacks

PARIS Sanofi's promising pipeline of experimental drugs can help it overcome setbacks including the low uptake of a new cholesterol treatment and concerns about a dengue vaccine, the French pharmaceuticals group said on Wednesday.

UPDATE 4-France's Sanofi pins hopes on new drugs after setbacks

* CEO says company on track to sell European generics unit (Adds CEO comments, details, updates shares)

Sanofi CEO says M&A targets in oncology are 'very expensive'

PARIS Sanofi's Chief Executive Olivier Brandicourt on Wednesday told investors that he considered M&A targets in oncology to be "very exensive".

Sanofi CEO says M&A targets in oncology are "very expensive"

PARIS, Dec 13 Sanofi's Chief Executive Olivier Brandicourt on Wednesday told investors that he considered M&A targets in oncology to be "very exensive".

Sanofi sees 9 regulatory submissions over next 18 months

PARIS, Dec 13 Sanofi said on Wednesday it saw its pipeline of new drugs supporting growth in the long term, and plans to file 9 regulatory applications over the next 18 months.

BRIEF-Regeneron And Sanofi Announce Positive Topline Pivotal Results For Pd-1 Antibody Cemiplimab In Advanced Cutaneous Squamous Cell Carcinoma

* REGENERON AND SANOFI ANNOUNCE POSITIVE TOPLINE PIVOTAL RESULTS FOR PD-1 ANTIBODY CEMIPLIMAB IN ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA

Sanofi investors hungry for drug progress and deal news

PARIS Sanofi still needs to convince markets it can deliver on an exciting and sustainable growth path as it contends with fresh difficulties in its vaccines arm and looks set for another gloomy year in diabetes, investors told Reuters.

Sanofi investors hungry for drug progress and deal news

PARIS, Dec 12 Sanofi still needs to convince markets it can deliver on an exciting and sustainable growth path as it contends with fresh difficulties in its vaccines arm and looks set for another gloomy year in diabetes, investors told Reuters.

FDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog

The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog.

Select another date: